September 17, 2021 | Kara
This week marked the exciting milestone of the official platform launch of the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), an initiative led by the Critical Path Institute (C-Path) to provide a centralised and standardised platform benefiting research and therapy development for the rare disease community.
“There is a lot of enthusiasm for seeing this platform become all it can be for patients and drug developers. It is not just about the data. This is a place to generate solutions in a highly collaborative way.”
“At Aridhia, we’re just delighted to be part of the RDCA-DAP ecosystem and to be able to make a contribution to the efforts to accelerate the discovery and development of therapies for rare conditions. The commitment of the community is outstanding and we’re proud to be a part of that.”
More than 350 million people globally are affected by rare diseases, yet rare diseases are particularly challenging to develop treatments for due to the small patient populations, lack of incentives, and difficulties gaining access to patient data.
RDCA-DAP is an FDA-funded cures accelerator dedicated to filling this gap for the rare disease community. C-Path has partnered with Aridhia Informatics to develop the platform which will serve as an integrated database and analytics hub that makes data more accessible for researchers and facilitate a collaborative environment for building novel tools that accelerate drug development.
The platform leverages the Aridhia DRE’s FAIR Data Services to bring together and centrally host rare disease data. Additionally, Workspaces provide on-demand analytical research environments. Throughout development, Aridhia and C-Path have engaged with community stakeholders through beta testing to understand and embrace feedback from researchers across academia and industry, patient advocates, and regulators.
RDCA-DAP is designed to connect groups across the rare disease community, such as patient registries, with quantitative modelers to develop disease progression models or provide regulators with a secure environment for evaluating new tools and methods for FDA approval.
At its heart, the platform fosters a collaborative ecosystem for the rare disease community by breaking down data silos and bridging the gap between patient groups and researchers to bring attention to more rare disease areas.
Following its public premiere (which is still viewable), the platform is ready to welcome a broad spectrum of users and will continue to develop as a central hub for data and research that directly benefits the rare disease community.